Core Viewpoint - The company has received a patent for a chemical luminescent immunoassay kit related to Alzheimer's disease, indicating progress in its product development [1]. Group 1 - The company has been asked by investors about the timeline for the market launch of its AD detection products [1]. - The company advises investors to monitor its official website and regular reports for updates on product sales and market launch information [1]. - The company has obtained an invention patent for the chemical luminescent immunoassay kit and its preparation method related to Alzheimer's disease [1].